AbbVie (ABBV) Net Cash Flow (2012 - 2026)
AbbVie (ABBV) posted quarterly Net Cash Flow of $4.2 billion for Q1 2026, up 1265.92% year-over-year from $305.6 million in Q1 2025, and up 1115.57% quarter-over-quarter from -$411.0 million in Q4 2025.
AbbVie (ABBV) Net Cash Flow (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Net Cash Flow for 15 consecutive years, with $4.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1265.92% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 132.64% YoY), while the FY2025 annual figure was -$337.0 million, up 95.34% from the prior year.
- Net Cash Flow grew to $4.2 billion in Q1 2026 per ABBV's latest filing, from -$411.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $5.3 billion in Q1 2024 and bottomed at -$5.9 billion in Q3 2024.
- Historically, Net Cash Flow has averaged -$15.5 million across 5 years, with a median of -$411.0 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 368.55% — and 2026, when it surged 1265.92%.
- AbbVie's Net Cash Flow stood at -$2.7 billion in 2022, then surged by 81.31% to -$496.0 million in 2023, then slumped by 240.12% to -$1.7 billion in 2024, then surged by 75.64% to -$411.0 million in 2025, then soared by 1115.57% to $4.2 billion in 2026.
- Business Quant data shows ABBV's Net Cash Flow at $4.2 billion in Q1 2026, -$411.0 million in Q4 2025, and -$830.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.84 Bn | 463.27 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 378.23 Bn | 371.09 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.01 Bn | 295.32 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 258.57 Bn | 253.67 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.36 Bn | 223.37 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 183.27 Bn | 180.09 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 160.74 Bn | 149.04 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 105.88 Bn | 101.72 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.28 Bn | 47.90 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.82 Bn |
| Jun 30, 2026 | -2.82 Bn |
| Mar 31, 2026 | 4.17 Bn |
| Mar 31, 2026 | 4.17 Bn |
| Dec 31, 2025 | -411.00 Mn |
| Dec 31, 2025 | -411.00 Mn |
| Sep 30, 2025 | -830.00 Mn |
| Sep 30, 2025 | -830.00 Mn |
| Jun 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Mar 31, 2025 | -358.00 Mn |
| Mar 31, 2025 | -358.00 Mn |
| Dec 31, 2024 | -1.69 Bn |
| Dec 31, 2024 | -1.69 Bn |
| Sep 30, 2024 | -5.88 Bn |
| Sep 30, 2024 | -5.88 Bn |
| Jun 30, 2024 | -4.93 Bn |
| Jun 30, 2024 | -4.93 Bn |
| Mar 31, 2024 | 5.27 Bn |
| Mar 31, 2024 | 5.27 Bn |